Immuneering plans Phase 2 trial of atebimetinib plus PD-1 blockade in lung cancer patients

• Immuneering flagged preclinical results showing atebimetinib can strengthen PD-1 checkpoint blockade in RAS-mutant tumor models.
• Findings will be presented at the SITC annual meeting on Nov. 6, 2026.
• Data supports a planned Phase 2 study pairing atebimetinib with PD-1 blockade in lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneering Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020900PRIMZONEFULLFEED9838124) on October 02, 2026, and is solely responsible for the information contained therein.